参考资料
[1]Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al., (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, https://doi.org/10.1016/S0140-6736(20)31604-4
[2]Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al., (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, https://doi.org/10.1016/S0140-6736(20)31605-6
[3]Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viralvectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020; 20: 816–26.
[4]Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, et al., (2020). Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. https://doi.org/10.1101/2020.07.17.20140533